Pharma Business - August 10, 2021
AstraZeneca’s Forxiga approved in the EU
Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes. The approval by the European Commission is based on positive results from the DAPA-CKD Phase III trial. The decision follows the recommendation for approval by the Committee […]
Collaboration - August 9, 2021
AstraZeneca and Regeneron collaborate
AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities. The companies will evenly split research and development costs and share equally in any future potential profits. “We are pleased to announce this important collaboration […]
Biotech Business - August 3, 2021
AstraZeneca’s Saphnelo approved in the US
Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. This marks the first regulatory approval for a type I interferon (type I IFN) receptor antagonist and the only new treatment approved for SLE in more than 10 […]
COVID-19 - July 28, 2021
New data about one dose of AstraZeneca’s Vaxzevria
Real-world data from Canada showed 82% and 87% effectiveness after one dose against hospitalization or death caused by Beta/Gamma and Delta variants respectively. Results from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of Canada and the Canadian Institutes of Health Research, published as a pre-print, demonstrated one dose of Vaxzevria […]
Pharma Business - July 19, 2021
AstraZeneca’s Imfinzi approved in China
Imfinzi has been approved in China for the 1st-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with standard of care platinum chemotherapy (etoposide plus a choice of either carboplatin or cisplatin). “Today’s approval of Imfinzi plus chemotherapy brings an important global standard of care to patients with extensive-stage small […]
Pharma Business - July 19, 2021
AstraZeneca’s Forxiga recommended for approval in the EU
Forxiga has been recommended for approval in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on results from the DAPA-CKD Phase III trial that showed Forxiga, […]
